N^e-乙酰基-N^a-Boc-L-赖氨酸 | 6404-26-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 赖氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N^e-乙酰基-N^a-Boc-L-赖氨酸
• 中文别名: N-叔丁氧羰基-N'-(乙酰基)-L-赖氨酸；N-叔丁氧羰基-N'-乙酰基-L-赖氨酸；N-叔丁氧羰基-N’-乙酰基-L-赖氨酸
• 英文名称: Boc-Lys(Ac)-OH
• 英文别名: N-α-(t-butoxycarbonyl)-N-ε-acetyl-L-lysine；(S)-6-acetamido-2-((tert-butoxycarbonyl)amino)hexanoic acid；(2S)-6-acetamido-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
• CAS: 6404-26-8
• 化学式: C₁₃H₂₄N₂O₅
• 分子量: 288.344
• InChiKey: IOKOUUAPSRCSNT-JTQLQIEISA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  528.8±45.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储温度应保持在0-5°C之间。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Boc-Lys(Ac)-OH
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Boc-Lys(Ac)-OH
Ingredient name:
CAS number: 6404-26-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H24N2O5
Molecular weight: 288.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N^e-乙酰基-N^a-Boc-L-赖氨酸 在 吡啶 、 水 、 C₇₃H₉₃N₁₅O₁₉S₂ 、 trypsin 、 三氯氧磷 作用下， 以 四氢呋喃 、 aq. phosphate buffer 为溶剂， 反应 5.0h， 生成 N-alpha-叔丁氧羰基-L-赖氨酸
  参考文献：
  名称：

  [EN] A GENETICALLY ENCODED, PHAGE-DISPLAYED CYCLIC PEPTIDE LIBRARY AND METHODS OF MAKING THE SAME
  [FR] BANQUE DE PEPTIDES CYCLIQUES CODÉS GÉNÉTIQUEMENT ET EXPRIMÉS EN SURFACE DE PHAGES, ET MÉTHODES DE PRODUCTION DE CELLE-CI

  摘要：

  本公开的实施例涉及一种选择循环肽结合靶标的方法，该方法通过将具有编码至少一个半胱氨酸和至少一个非规范氨基酸的组合区域的噬菌体外壳蛋白基因的核酸库转化为细菌宿主细胞来实现。转化导致产生带有噬菌体外壳蛋白的噬菌体颗粒，其中半胱氨酸和非规范氨基酸耦合形成循环肽库。然后，对所需的靶标筛选噬菌体颗粒以选择结合的循环肽。然后确定所选择的循环肽的氨基酸序列。本公开的其他实施例涉及构建编码循环肽的噬菌体外显库的方法。本公开的其他实施例涉及所产生的循环肽、噬菌体外显库和噬菌体颗粒。

  公开号：

  WO2020236146A1
• 作为产物：
  描述：

  乙酸酐 、 N-alpha-叔丁氧羰基-L-赖氨酸 以 水 、 乙腈 为溶剂， 生成 N^e-乙酰基-N^a-Boc-L-赖氨酸
  参考文献：
  名称：

  Inhibitors selective for HDAC6 in enzymes and cells

  摘要：

  Histone deacetylase inhibitors with anticancer or anti-inflammatory activity bind to Class I or Class I and II HDAC enzymes. Here we compare selectivity of inhibitors of a Class II HDAC enzyme (HDAC6) and find one that retains high selectivity in macrophages. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.100

文献信息

• SUBSTITUTED ANTHRAQUINONE DYES FOR CELLULAR STAINS AND ENZYME DETECTION
  申请人：Mao Fei

  公开号：US20120252063A1

  公开（公告）日：2012-10-04

  The invention discloses new substituted anthraquinone dyes that may be useful as cellular stains. In some aspect of the invention, the nuclear stains are useful for staining the nuclei of dead or fixed cells. Another aspect of the invention relates to substituted anthraquinone dyes comprising an enzyme substrate moiety that is transformable or cleavable by an enzyme such that the transformation or cleavage of the substrate moiety causes a detectable change in the functionality or spectral properties of the dye.

  本发明公开了新的取代蒽醌染料，可能用作细胞染料。在发明的某些方面，核染料可用于染色死亡或固定细胞的细胞核。发明的另一方面涉及包含可由酶转化或切割的酶底物部分的取代蒽醌染料，使得底物部分的转化或切割导致染料的功能性或光谱性质发生可检测的变化。
• Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs.
  作者：KEIICHI KAMISANGO、IKUO SAIKI、YOSHIRO TANIO、SHIGERU KOBAYASHI、TSUNEHIKO FUKUDA、ISAO SEKIKAWA、ICHIRO AZUMA、YUICHI YAMAMURA

  DOI：10.1248/cpb.29.1644

  日期：——

  Twenty-two kinds of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs were synthesized and their adjuvant activity on the induction of delayed-type hypersensitivity to ABA-N-acetyl-L-tyrosine was examined. The L-alanine residue of MDP could be replaced with certain other amino acid residues without loss of activity. The structureactivity relationship of these compounds is discussed. With respect to replacement of the L-alanine residue of MDP in connection with adjuvant activity, it was shown that (1) amino acids having a suitable side chain were effective, (2) basic amino acids were unfavorable, (3) aromatic amino acids were unfavorable, and (4) acidic amino acids were effective. The D-isoglutamine residue of MDP was considered to be essential for the adjuvant activity. The adjuvant activity was decreased by esterification with methanol of the D-glutamic acid residue of MDP and related N-acetylmuramyldipeptides, but the adjuvant activity of D-glutamic acid diamide analogs was similar to that of MDP and its analogs.

  合成了二十二种N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺(MDP)的类似物,并检验了它们对诱导对ABA＿N-乙酰-L-酪氨酸的迟发型过敏反应的佐剂活性。MDP的L-丙氨酸残基能为某些其他氨基酸残基所置换,而活性不变。讨论了这些化合物的结构-活性关系。关于MDP中L-丙氨酸残基的置换和佐剂活性,表明; (1)具有合适侧链的氨基酸是有效的; (2)碱性氨基酸不是有利的; (3)芳香族的氨基酸不是有利的; (4)酸性氨基酸是有效的。认为MDP的D-异谷氨酰胺残基对佐剂活性是必要的。与MDP和有关N-乙酰胞壁酰二肽的D-谷氨酸残基的酯化作用使佐剂活性降低,但D-谷氨酸二酰胺类似物的佐剂活性与MDP及其类似物的佐剂活性相似。
• [EN] NOVEL GLUTAMINE ANTAGONISTS AND USES THEREOF<br/>[FR] NOUVEAUX ANTAGONISTES DE LA GLUTAMINE ET LEURS UTILISATIONS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2019071110A1

  公开（公告）日：2019-04-11

  Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.

  谷氨酰胺拮抗剂及其用于治疗肿瘤、免疫和神经系统疾病的方法已被披露。还披露了治疗肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。还披露了增强免疫检查点抑制剂效果的方法，使受试者对免疫检查点抑制剂产生反应，或减少免疫检查点抑制剂的毒性或剂量或治疗次数的方法，包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量，以及免疫检查点抑制剂。还披露了治疗对检查点抑制剂疗法无效的肿瘤、免疫、传染性或神经系统疾病或紊乱的方法，该方法包括向需要治疗的受试者施用本公开的谷氨酰胺拮抗剂或其药物组成的治疗有效量。
• Histone deacetylase inhibitors: synthesis of cyclic tetrapeptides and their triazole analogs
  作者：Erinprit K. Singh、Lidia A. Nazarova、Stephanie A. Lapera、Leslie D. Alexander、Shelli R. McAlpine

  DOI：10.1016/j.tetlet.2010.06.050

  日期：2010.8

  Synthesis of nine macrocyclic peptide HDAC inhibitors and three triazole derivatives is described. HDAC inhibitory activity of these compounds against HeLa cell lysate is evaluated. The biological data demonstrate that incorporation of a triazole unit improves the HDAC inhibitory activity.

  描述了九个大环肽 HDAC 抑制剂和三个三唑衍生物的合成。评估了这些化合物对 HeLa 细胞裂解物的 HDAC 抑制活性。生物学数据表明，三唑单元的掺入提高了 HDAC 抑制活性。
• [EN] REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO<br/>[FR] CATALYSEURS DE COUPLAGE DE DÉSHYDRATATION RÉDOX ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：UNIV EMORY

  公开号：WO2017070157A1

  公开（公告）日：2017-04-27

  This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle. Catalytic molecules disclosed herein are useful as catalysts in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations.

  这份披露涉及使用催化分子的合成偶联方法。在某些实施例中，这些催化分子包括杂环硫酰胺、S-酰基硫代水杨酰胺、二硫化物、含硒杂环、二硒化合物、二碲化合物或含碲杂环。本文披露的催化分子可用作催化剂，用于将含羟基化合物转化为酰胺、酯、酮和其他碳到杂原子或碳到碳的转化过程中。